Cardiovascular Disease

Researchers compared four blood-based brain injury biomarkers across multiple centers to evaluate how reliably they estimate the extent of brain damage in unconscious patients after cardiac arrest

From biomarkers to imaging, new lab-based diagnostics are transforming how cardiovascular risk is detected and managed

Analysis of 300 million patient records shows only 0.2 percent of the US population has been tested for lipoprotein(a)

Study highlights overlooked heart attack causes in adults under 65, challenging long-held beliefs and revealing risks of misdiagnosis

Fully automated platforms and diagnostics partnerships are essential for clinical labs to manage increasing cardiometabolic test volumes

At the ADLM 2025, Roche highlights advances in diagnostics, including digital health solutions, mass spectrometry, and expanded access to testing across care settings

The National Lipid Association recommends all adults measure their lipoprotein (a) at least once in a lifetime to help assess cardiovascular risk

Recent findings from scientists at St. Jude Children’s Research Hospital are showing promise for assessing cardiomyopathy risk in childhood cancer survivors

To capture new demand, clinical labs should note advancing technology and rising disease mortality

The new test will allow clinicians to identify individuals at risk of a life-threatening genetic heart arrhythmia